CD30 Ligand: Cloning, Characterisation and Biological Activities

  • Hans-Jürgen. Gruss
  • Steven. K. Dower
Part of the NATO ASI Series book series (NSSA, volume 280)


Hodgkin’s disease (HD) is characterised by the presence of a small number (< 1% of total tumour mass) of the typical, presumed malignant Hodgkin and Reed-Sternberg (H-RS) cells in a hyperplastic background of normal, reactive lymphocytes, plasma cells, histiocytes, neutrophils, eosinophils, and stromal cells. The histopathological presentation and characteristic clinical features of HD correlate with an unbalanced production of multiple cytokines. H-RS cells produce various growth factors, cytokine receptors and activation antigens, implying a role for growth factors in the pathophysiology of HD. HD may therefore be characterised as a tumour of cytokine producing cells. The CD30 antigen has been described as a marker for cultured and primary H-RS cells, and found to be overexpressed in HD and some large cell anaplastic non-Hodgkin’s lymphoma cases. The molecular cloning of the CD30 antigen revealed that CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily. The cloning of the cognate for CD30, currently termed CD30 ligand, confirmed that the CD30 antigen functions as a cytokine receptor. Recombinant CD30 ligand is a type-II membrane-associated protein with pleiotropic biological activities for different CD30+ lymphoma types, but also normal immune system cells, predominantly T-cells. CD30L belongs to the emerging tumour necrosis factor ligand superfamily by virtue of homology to CD27L, CD40L, TNF and other members. These findings suggest that CD30-CD30L interactions could have a pathophysiological role in HD and large cell anaplastic lymphomas, and could also be involved in the activation and function of the immune system, particularly T-cell responses.


Large Cell Anaplastic Lymphoma CD30 Monoclonal Antibody CD30L Expression Cytokine Produce Cell Burkitt Lymphoma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH (1993) FAS transduces activation signals in normal human T lymphocytes. J Exp Med 178:2231PubMedCrossRefGoogle Scholar
  2. Alderson MR, Smith CA, Tough TW, Davis-Smith T, Armitage RJ, Falk B, Roux E, Baker E, Sutherland GR, Din WS, Goodwin RG (1994) Molecular and biological characterisation of human 4-1BB and its ligand. Eur J Immunol 24:2219PubMedCrossRefGoogle Scholar
  3. Andreesen R, Brugger W, Löhr GW, Bross KJ (1989) Human macrophages can express the Hodgkin’s cell-associated antigen Ki-1 (CD30). Am J Pathol 134:187PubMedGoogle Scholar
  4. Armitage RJ, Maliszewski CR, Alderson MR, Grabstein KH, Spriggs MK. Fanslow WC (1993) CD40L. A multi-functional ligand. Semin Immunol 5:401PubMedCrossRefGoogle Scholar
  5. Delabie J, Ceuppens JL, Vandenberghe P, de Boer M, Coorevits L, de Wolf-Peeters C (1993) The B7/BB-1 antigen is expressed by Reed-Sternberg cells of Hodgkin’s disease and contributes to the stimulating capacity of Hodgkin’s disease-derived cell lines. Blood 82:2845PubMedGoogle Scholar
  6. Drexler HG (1992) Recent results on the biology of Hodgkin and Reed-Sternberg cells. 1. Biopsy material. Leuk Lymphoma 8:283PubMedCrossRefGoogle Scholar
  7. Drexler HG (1993) Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 9:1PubMedCrossRefGoogle Scholar
  8. Drexler HG, Jones DB, Diehl V, Minowada J (1989) Is the Hodgkin cell a T-or B-lymphocyte? — Recent evidence from geno-and immunophenotypic analysis and in-vitro cell lines. Hematol Oncol 7:95PubMedCrossRefGoogle Scholar
  9. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 68:421PubMedCrossRefGoogle Scholar
  10. Eck M, Sprang S (1989) The structure of tumour necrosis factor-gamma at 2.6 Å resolution. J Biol Chem 264:17595PubMedGoogle Scholar
  11. Ellis TM, Simms PE, Slivnick DJ, Jäck H-M, Fisher RI (1993) CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 151:2380PubMedGoogle Scholar
  12. Farrah T, Smith CA (1992) An emerging cytokine family. Nature 358:26PubMedCrossRefGoogle Scholar
  13. Froese P, Lemke H, Gerdes J, Havsteen B, Schwarting BR, Hansen H, Stein H (1987) Biochemical characterisation and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. J Immunol 139:2081PubMedGoogle Scholar
  14. Gause A, Scholz R, Klein S, Jung W, Diehl V, Tesch H, Pfreundschuh M (1991) Increased levels of circulating interleukin-6 in patients with Hodgkin’s disease. Haematol Oncol 9:307CrossRefGoogle Scholar
  15. Gruss H-J, Brach MA, Drexler HG, Bonnifer R, Mertelsmann RH, Herrmann F (1992) Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res 52:3353PubMedGoogle Scholar
  16. Gruss H-J, Dölken G, Brach MA, Mertelsmann R, Herrmann F (1993 a) Serum levels of circulating ICAM-1 are increased in Hodgkin’s disease. Leukemia 7:1245PubMedGoogle Scholar
  17. Gruss H-J, Dölken G, Brach MA, Mertelsmann R, Herrmann F (1993b) The significance of 60 kDa soluble TNF receptors in patients with Hodgkin’s disease. Leukemia 7:1339PubMedGoogle Scholar
  18. Gruss H-J, Herrmann F, Drexler HG (1994a) Hodgkin’s disease, a tumor of cytokine producing cells. Crit Rev Oncogen 5:473Google Scholar
  19. Gruss H-J, DaSilva N, Hu ZB, Uphoff CC, Goodwin RG, Drexler HG (1994b) Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 8:2083PubMedGoogle Scholar
  20. Gruss H-J, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG (1994c) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83:2045PubMedGoogle Scholar
  21. Gruss H-J, Hirschstein D, Wright B, Ulrich D, Caligiuri MA, Strockbine L, Armitage RJ, Dower SK (1994d) Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin’s disease. Blood 84:2305PubMedGoogle Scholar
  22. Gruss H-J, Dower SK (1995) Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 85:3378PubMedGoogle Scholar
  23. Herbst H, Stein H, Niedobitek G (1993) Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncogen 4:91Google Scholar
  24. Jones EY, Stuart DI, Walker NP (1990) The three-dimensional structure of tumour necrosis factor. Prog Clin Biol Res 349:321PubMedGoogle Scholar
  25. Kaplan HS (1980) Hodgkin’s disease. (Boston: Harvard University Press)Google Scholar
  26. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM (1994) In vivo expression of the B7 co-stimulatory molecule by subsets of antigen-presenting cells and malignant cells of Hodgkin’s disease. Blood 83:793PubMedGoogle Scholar
  27. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H, Pizzolo G (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin’s disease and correlate with clinical features and prognosis. J Clin Oncol 12:793PubMedGoogle Scholar
  28. Pizzolo G, Vinante F, Nadali G, Ricetti MM, Morosato L, Marrocchella R, Vincenzi C, Semenzaio G, Chilosi M (1993) ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin’s disease. Br J Haematol 84:161PubMedCrossRefGoogle Scholar
  29. Poppema S (1989) The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin’s disease. Am J Pathol 135:351PubMedGoogle Scholar
  30. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature 299:65PubMedCrossRefGoogle Scholar
  31. Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H (1989) BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74:65Google Scholar
  32. Smith CA, Gruss H-J, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, Brannan CI, Copeland NG, Jenkins NA, Grabstein KH, Gliniak B, McAlister IB, Fanslow W, Alderson M, Falk B, Gimpel S, Gillis S, Din WS, Goodwin RG, Armitage RJ (1993) CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349PubMedCrossRefGoogle Scholar
  33. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, co-stimulation and death. Cell 76:959PubMedCrossRefGoogle Scholar
  34. Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl V (1982) Identification of Hodgkin and Sternberg-Reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer 30:445PubMedCrossRefGoogle Scholar
  35. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K (1985) The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848PubMedGoogle Scholar
  36. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the FAS ligand, a novel member of the tumour necrosis factor family. Cell 75:1169PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Hans-Jürgen. Gruss
    • 1
    • 2
  • Steven. K. Dower
    • 1
  1. 1.Department of BiochemistryImmunex Research and Development CorporationSeattleUSA
  2. 2.Department of Medical Oncology and Applied Molecular Biology, Virchow Klinikum Robert-Rössle Cancer Center and Max Delbruck Center for Molecular MedicineBerlinGermany

Personalised recommendations